Clinical evaluation of pertussis vaccines: US food and drug administration regulatory considerations

Journal of Infectious Diseases

Volumn 209, Issue SUPPL. 1, 2014, Pages

  Farizo, Karen M ^a   Burns, Drusilla L ^a   Finn, Theresa M ^a   Gruber, Marion F ^a   Pratt, R Douglas ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

pertussis vaccines; regulatory pathways; vaccine effectiveness

Indexed keywords

PERTUSSIS VACCINES; REGULATORY PATHWAYS; VACCINE EFFECTIVENESS;

COMMUNICABLE DISEASES, EMERGING; DRUG APPROVAL; HUMANS; PERTUSSIS VACCINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WHOOPING COUGH;

EID: 84899008686     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit532     Document Type: Article

References (14)

1. Code of Federal Regulations. 21 CFR 600.3. Biological products: General, subpart A, definitions
2. Guidance for industry: Providing clinical evidence of effectiveness for human drugs and biological products. Rockville, MD: US Food and Drug Administration, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, 1998. http://www.fda. gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/ Guidances/General/ucm217041.htm#1998. Accessed 22 October 2013
3. Code of Federal Regulations. 21 CFR §201.57. Specific requirements on content and format of labeling for human prescription drug and biological products described in § 201.56(.b)(.1).
4. Code of Federal Regulations. 21 CFR §314.126. Adequate and wellcontrolled studies
5. Code of Federal Regulations. 21 CFR §601. Subpart E accelerated approval of biological products for serious or life-Threatening illnesses
6. Guidance for industry: Clinical data needed to support the licensure of seasonal inactivated influenza vaccines. Rockville, MD: US Food and Drug Administration, Center for Biologics Evaluation and Research, 2007. http://www.fda.gov/BiologicsBloodVaccines/GuidanceCompliance RegulatoryInformation/Guidances/Vaccines/ucm074794.htm. Accessed 16 September 2013
7. Klein DL. Multicenter acellular pertussis vaccine trial: A National Institutes of Health perspective. Pediatrics 1995; 96:547-8
8. WHO meeting on case definition of pertussis, Geneva, 10-11 January 1991. Geneva, Switzerland: World Health Organization, 1991:4-5. http:// apps.who.int/iris/handle/10665/66921. Accessed 22 October 2013
9. Güris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: Increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999; 28:1230-7
10. Centers for Disease Control and Prevention. Pertussis - United States 1997-2000. MMWR 2002; 51:73-6
11. Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012; 308:2126-32
12. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012; 367:1012-9
13. Tartof SY, Lewis M, Kenyon C, et al.Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 2013; 131:e1047-52
14. Centers for Disease Control and Prevention. Pertussis epidemic - Washington, 2012. MMWR 2012; 61:517-22